🚀 VC round data is live in beta, check it out!
PCI Biotech Holding Valuation Multiples
Discover revenue and EBITDA valuation multiples for PCI Biotech Holding and similar public comparables like Nidhogg Resources Holding, IO Biotech, Oxurion, Lidds and more.
PCI Biotech Holding Overview
About PCI Biotech Holding
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
Founded
2007
HQ
Employees
7
Website
Sectors
Financials (FY)
Market Cap
$618K
PCI Biotech Holding Financials
PCI Biotech Holding reported last fiscal year revenue of — and negative EBITDA of ($2M).
In the same fiscal year, PCI Biotech Holding generated ($2M) in EBITDA losses and had net loss of ($2M).
PCI Biotech Holding P&L
In the most recent fiscal year, PCI Biotech Holding reported revenue of — and EBITDA of ($2M).
PCI Biotech Holding expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PCI Biotech Holding Stock Performance
PCI Biotech Holding has current market cap of $618K.
Market Cap Evolution
PCI Biotech Holding's stock price is $0.02.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $618K | -0.1% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPCI Biotech Holding Valuation Multiples
PCI Biotech Holding trades at 0.5x EV/EBITDA.
PCI Biotech Holding Financial Valuation Multiples
As of April 19, 2026, PCI Biotech Holding has market cap of $618K.
Equity research analysts estimate PCI Biotech Holding's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PCI Biotech Holding has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $618K | XXX | $618K | XXX | XXX | XXX |
| EV (current) | ($806K) | XXX | ($806K) | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 0.4x | XXX | XXX | XXX |
| P/E | — | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PCI Biotech Holding Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PCI Biotech Holding Margins & Growth Rates
PCI Biotech Holding's revenue in the last fiscal year grew by —.
PCI Biotech Holding's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
PCI Biotech Holding Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (19%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PCI Biotech Holding Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PCI Biotech Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Nidhogg Resources Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| IO Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxurion | XXX | XXX | XXX | XXX | XXX | XXX |
| Lidds | XXX | XXX | XXX | XXX | XXX | XXX |
| bioXXmed | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PCI Biotech Holding M&A Activity
PCI Biotech Holding acquired XXX companies to date.
Last acquisition by PCI Biotech Holding was on XXXXXXXX, XXXXX. PCI Biotech Holding acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PCI Biotech Holding
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPCI Biotech Holding Investment Activity
PCI Biotech Holding invested in XXX companies to date.
PCI Biotech Holding made its latest investment on XXXXXXXX, XXXXX. PCI Biotech Holding invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PCI Biotech Holding
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PCI Biotech Holding
| When was PCI Biotech Holding founded? | PCI Biotech Holding was founded in 2007. |
| Where is PCI Biotech Holding headquartered? | PCI Biotech Holding is headquartered in Norway. |
| How many employees does PCI Biotech Holding have? | As of today, PCI Biotech Holding has over 7 employees. |
| Is PCI Biotech Holding publicly listed? | Yes, PCI Biotech Holding is a public company listed on Oslo Børs. |
| What is the stock symbol of PCI Biotech Holding? | PCI Biotech Holding trades under PCIB ticker. |
| When did PCI Biotech Holding go public? | PCI Biotech Holding went public in 2008. |
| Who are competitors of PCI Biotech Holding? | PCI Biotech Holding main competitors are Nidhogg Resources Holding, IO Biotech, Oxurion, Lidds. |
| What is the current market cap of PCI Biotech Holding? | PCI Biotech Holding's current market cap is $618K. |
| Is PCI Biotech Holding profitable? | No, PCI Biotech Holding is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.